News | July 03, 2024
LG Chem enters Chinese osteoarthritis treatment market
Partners with Yifan Pharmaceutical to launch Synovian injection for osteoarthritis in China
Partners with Yifan Pharmaceutical to launch Synovian injection for osteoarthritis in China
LG Chem is making progress in the development of the world's first oral treatment for rare forms of obesity.
LG Chem will receive totaling up to $95.5 million for the China rights
With this designation, LG Chem will receive benefits such as exclusive sales rights in the US market for seven years, subsidies and tax cuts for clinical testing costs in the US, and preliminary consulting support related to development
Phase 3 clinical trial designed to evaluate the safety and efficacy of tivozanib in combination with nivolumab
Subscribe To Our Newsletter & Stay Updated
